Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | TNKS | O95271 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.42 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312399 | 0.81 | KDM4E (0.62) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL311467 | 0.78 | KDM4E (0.48) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL312246 | 0.78 | KDM4E (0.48) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL311979 | 0.78 | CYP1B1 (0.48) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL311824 | 0.78 | CSNK2A2 (0.53) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL312123 | 0.77 | KDM4E (0.47) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| SCHEMBL311324 | 0.76 | NPC1 (0.60) | KDM4ESMN1; SMN2TNKSCYP3A4MAPT | |
| SCHEMBL311321 | 0.75 | CSNK2A2 (0.67) | KDM4ESMN1; SMN2CYP3A4MAPTHPGD | |
| SCHEMBL13945258 | 0.73 | CYP1A2 (0.56) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 | |
| Hydrochloric Acid SCHEMBL1647048 | 0.72 | CYP1A2 (0.55) | KDM4ESMN1; SMN2PARP1TNKSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | claimed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | claimed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | claimed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | claimed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | claimed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | KDM4E 2334/4885SMN1; SMN2 1664/4885PARP1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.